Subcutaneous infliximab therapy alone is associated with higher immunogenicity than IV infliximab and an immunomodulator combined.

Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology practices, ...

Education before subcutaneous daratumumab administration can both reassure patients and reduce the occurrence of adverse ...

The results feed into an effort to identify to monoclonal antibody combinations that would prevent and possibly treat HIV ...

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety ...

Wegovy (semaglutide) is approved by the U.S. Food and Drug Administration (FDA) for weight loss and weight management in ...

ASCO: new Sarclisa data support subcutaneous administration with on-body injector . New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via a ...

Eden, the leading health platform connecting individuals with independent licensed providers and pharmacies focused on ...

Bristol Myers Squibb receives European approval for subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Thursday, May 29, 2025, 15:0 ...